Business Description
Oryzon Genomics SA
ISIN : ES0167733015
Total Employee Number:
44Description
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.87 | |||||
Equity-to-Asset | 0.84 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | -0.65 | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 12.8 | |||||
3-Year EPS without NRI Growth Rate | 23.6 | |||||
3-Year FCF Growth Rate | 15.9 | |||||
3-Year Book Growth Rate | 5.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -263.03 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 61.08 | |||||
9-Day RSI | 61.93 | |||||
14-Day RSI | 62 | |||||
3-1 Month Momentum % | 11.17 | |||||
6-1 Month Momentum % | -2.64 | |||||
12-1 Month Momentum % | 13.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11.4 | |||||
Shareholder Yield % | 0.58 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -1.74 | |||||
ROA % | -1.42 | |||||
ROIC % | -3.7 | |||||
3-Year ROIIC % | 2.72 | |||||
ROC (Joel Greenblatt) % | -3396.29 | |||||
ROCE % | -9.14 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 523.33 | |||||
PB Ratio | 2.09 | |||||
Price-to-Tangible-Book | 2.09 | |||||
EV-to-EBIT | -18.93 | |||||
EV-to-Forward-EBIT | -29.52 | |||||
EV-to-EBITDA | -19.03 | |||||
EV-to-Forward-EBITDA | -30 | |||||
EV-to-Forward-Revenue | 29.2 | |||||
EV-to-FCF | -16.48 | |||||
Earnings Yield (Greenblatt) % | -5.28 | |||||
FCF Yield % | -5.45 |
GF Value™
Oryzon Genomics SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Oryzon Genomics SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 132 days | ||
| Second quarter earnings results for 2026 | 2026-07-30 | In 33 days | ||
| General meeting for 2026 | 2026-06-26 | 3.13 (-0.82%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 2.75 (-1.50%) | ||
| Annual report for 2025 | 2026-02-27 | 3.22 (+0.47%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-27 | 3.22 (+0.47%) | ||
| 44th Annual J.P. Morgan Healthcare Conference | 2026-01-12 | 3.18 (-0.16%) | ||
| 9th Sachs Annual Neuroscience Innovation Forum | 2026-01-11 10:35 | 3.18 (-0.16%) | ||
| Third quarter earnings results for 2025 | 2025-11-07 | 3.36 (-1.18%) | ||
| Second quarter earnings results for 2025 | 2025-07-30 | 2.71 (-0.37%) |
Show
Entries
Articles on Oryzon Genomics SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers